CEO
Leyden Labs
Leyden Labs is a clinical-stage biotechnology company developing intranasal antibody sprays designed to provide immediate, broad-spectrum protection against respiratory viruses at the airway mucosa. The company's lead programs, including PanFlu™, have advanced into clinical development, aiming to overcome limitations of vaccine-based protection by stopping infection at the point of viral entry.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Updated 3 days ago
Funding
Raised to date
$303MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$146.3M across 3 disclosed rounds
+6€40M · Series C
Announced Jun 2026
Disclosed cumulative: $146.3M
3/3
Reported total $303M
Incomplete round history. $156.7M of the $303M reported total isn’t matched to a known round.
RoundDateAmountValuationInvestors
Founders
Product
Problem
Respiratory viruses, including influenza and COVID-19, exhibit asymptomatic spread, making it difficult to prevent initial infections and subsequent transmission. Current methods often fail to provide immediate protection at the point of entry, the nasal mucosa, leaving individuals vulnerable to infection regardless of their immune history.
Solution
Leyden Labs develops nasal sprays that deliver antibodies directly to the nasal mucosa, providing immediate antiviral protection against respiratory viruses. This approach aims to stop the initial infection, preventing onward transmission, and offers broad protection against existing and emerging viral strains. By targeting conserved epitopes across viral families, the sprays provide universal protection, independent of an individual's immune history or comorbidities. The company's technology harnesses mucosal immunity, optimizing the administration of intranasally-delivered antibodies to efficiently target invading virus particles and engage the immune system. Two complementary lead programs have advanced into clinical development, supported by robust preclinical studies.
Target Audience
The primary target audience includes individuals seeking immediate protection against respiratory viruses, as well as public health organizations and governments preparing for future pandemics.
Features
- Nasal spray formulation for direct delivery of antibodies to the nasal mucosa
- Broad-spectrum protection targeting conserved epitopes across multiple respiratory viruses
- Designed to prevent initial infection and onward transmission of viruses
- Utilizes modified antibodies optimized for mucosal administration
- Lead program, PanFlu™, is currently in clinical trials
- Aims for accessible and self-administrable products for autonomous protection
- Combines world-class molecules, formulation science expertise, and targeted airway delivery capabilities